Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can antiepileptic drugs unmask a susceptibility to psychiatric disorders?

Abstract

Psychiatric adverse events have been associated with rapid titration and high doses of most antiepileptic drugs (AEDs). However, several AEDs can cause such events at any dose. These agents include barbiturates, topiramate, levetiracetam and zonisamide. A search of the literature reveals that psychiatric adverse events associated with these AEDs seem not to occur at random. Rather, they are most likely to be reported by patients who have an inherent vulnerability to psychiatric disorders; that is, those with a personal or family history of psychiatric illness. In a recent study by Mula et al., patients who underwent rapid titration of topiramate had a fivefold increase in risk of depressive episodes. In patients with a history of depression, however, the risk increase was 23.3-fold. Thus, clinicians must ascertain a patient's personal and family psychiatric history before choosing an AED and planning the dose titration regimen.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Brent DA et al. (1987) Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 80: 909–917

    CAS  PubMed  Google Scholar 

  2. Levinson DF and Devinsky O (1999) Psychiatric adverse events during vigabatrin therapy. Neurology 53: 1503–1511

    Article  CAS  Google Scholar 

  3. Leppik IE (1995) Tiagabine: the safety landscape. Epilepsia 36 (Suppl 6): S10–S13

    Article  CAS  Google Scholar 

  4. Mula M et al. (2003) Psychiatric adverse events during levetiracetam therapy. Neurology 61: 704–706

    Article  CAS  Google Scholar 

  5. Mula M et al. (2003) Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 48: 2322–2326

    Google Scholar 

  6. Trimble RM et al. (2000) Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 9: 249–254

    Article  CAS  Google Scholar 

  7. Kanner AM et al. (2003) A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4: 548–552

    Article  Google Scholar 

  8. Mula M et al. (2008) The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia [10.1111/j.1528-1167.2008.01799.x]

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

Dr Kanner has acted as a consultant, been a member of speakers' bureaus or received honoraria from GlaxoSmithKline, Ortho-McNeill, Pfizer, and UCB. He has received grant or research support from GlaxoSmithKline and Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanner, A. Can antiepileptic drugs unmask a susceptibility to psychiatric disorders?. Nat Rev Neurol 5, 132–133 (2009). https://doi.org/10.1038/ncpneuro1051

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro1051

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing